Список литературы.

Поставить закладку

Gupta A. Primary Immunodeficiency Disorders: Where Do We Stand? // Indian J. Pediatr. 2019. Vol. 86, № 10. P. 873–874.
Hartono S. et al. Gastrointestinal Disorders Associated with Primary Immunodeficiency Diseases // Clin. Rev. Allergy Immunol. 2019. Vol. 57, № 2. P. 145–165.
Bonilla F.A. et al. Practice parameter for the diagnosis and management of primary immunodeficiency // J. Allergy Clin. Immunol. 2015. Vol. 136, № 5. P. 1186–1205.
Rezaei N. et al. An Introduction to Primary Immunodeficiency Diseases // Primary Immunodeficiency Diseases. Berlin, Heidelberg: Springer Berlin Heidelberg, 2008. P. 1– 38.
Locke B.A., Dasu T., Verbsky J.W. Laboratory Diagnosis of Primary Immunodeficiencies // Clin. Rev. Allergy Immunol. 2014. Vol. 46, № 2. P. 154–168.
Bonilla F.A. Memory Switched B Cell Percentage and Not Serum Immunoglobulin Concentration Is Associated With Clinical Complications in Children and Adults With Specific Antibody Deficiency and Common Variable Immunodeficiency // Pediatrics. 2007. Vol. 120, № Supplement 3. P. S156.1-S156.
Aghamohammadi A. et al. Predominantly Antibody Deficiencies // Primary Immunodeficiency Diseases. Berlin, Heidelberg: Springer Berlin Heidelberg, 2017. P. 183–244.
Fried A.J., Bonilla F.A. Pathogenesis, Diagnosis, and Management of Primary Antibody Deficiencies and Infections // Clin. Microbiol. Rev. 2009. Vol. 22, № 3. P. 396–414.
Латышева Е.А. Первичные иммунодефициты у взрослых. Преимущественное нарушение синтеза антител // Терапия. 2018. № 7-8 (25-26). P. 119–124.
van der Burg M. et al. New frontiers of primary antibody deficiencies // Cell. Mol. Life Sci. 2012. Vol. 69, № 1. P. 59–73.
Picard C. et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity // J. Clin. Immunol. 2018. Vol. 38, № 1. P. 96–128.
Bogaert D.J.A. et al. Genes associated with common variable immunodeficiency: one diagnosis to rule them all? // J. Med. Genet. 2016. Vol. 53, № 9. P. 575–590.
Tangye S.G. et al. Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee // J. Clin. Immunol. 2020.
Bonilla F.A. et al. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders // J. Allergy Clin. Immunol. Pract. 2016. Vol. 4, № 1. P. 38– 59.
Wood P.M. Primary antibody deficiency syndromes // Curr. Opin. Hematol. 2010. Vol. 17, № 4. P. 356–361.
Латышева Е.А. et al. Первичные иммунодефициты у взрослых - анализ регистра института иммунологии // Российский аллергологический журнал. 2018. № 4. P. 17– 25.
Abbott J.K., Gelfand E.W. Common Variable Immunodeficiency // Immunol. Allergy Clin. North Am. 2015. Vol. 35, № 4. P. 637–658.
Javier F.C., Moore C.M., Sorensen R.U. Distribution of primary immunodeficiency diseases diagnosed in a pediatric tertiary hospital // Ann. Allergy, Asthma Immunol. 2000. Vol. 84, № 1. P. 25–30.
Щербина А.Ю., Кузьменко Н.Б. Классификация первичных иммунодефицитов как отражение современных представлений об их патогенезе и терапевтических подходах. 2017. № 3. P. 51–57.
World Health Organization. International statistical classification of diseases and related health problems. - 10th revision, volume 1 tabilar list, Fifth edition, 2016. 2016. 242–244 p.
Bierry G. et al. Thoracic Manifestations of Primary Humoral Immunodeficiency: A Comprehensive Review // RadioGraphics. 2009. Vol. 29, № 7. P. 1909–1920.
Hampson F.A. et al. Respiratory disease in common variable immunodeficiency and other primary immunodeficiency disorders // Clin. Radiol. 2012. Vol. 67, № 6. P. 587–595.
Латышева Т.В. et al. Пульмунологические проявления у взрослых пациентов с дефектом гуморального звена иммунитета // Терапевтический архив. 2016. № 8. P. 127–134.
Suri D., Rawat A., Singh S. X-linked Agammaglobulinemia // Indian J. Pediatr. 2016. Vol. 83, № 4. P. 331–337.
Abolhassani H. et al. A review on guidelines for management and treatment of common variable immunodeficiency // Expert Rev. Clin. Immunol. 2013. Vol. 9, № 6. P. 561–575.
Chapel H. et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes // Blood. 2008. Vol. 112, № 2. P. 277–286.
Popa V., Colby T. V., Reich S.B. Pulmonary Interstitial Disease in Ig Deficiency // Chest. 2002. Vol. 122, № 5. P. 1594–1603.
Jesenak M. et al. Pulmonary Manifestations of Primary Immunodeficiency Disorders in Children // Front. Pediatr. 2014. Vol. 2.
Verbsky J., Routes J. Sarcoidosis and Common Variable Immunodeficiency: Similarities and Differences // Semin. Respir. Crit. Care Med. 2014. Vol. 35, № 03. P. 330–335.
Uzzan M. et al. Gastrointestinal Disorders Associated with Common Variable Immune Deficiency (CVID) and Chronic Granulomatous Disease (CGD) // Curr. Gastroenterol. Rep. 2016. Vol. 18, № 4. P. 17.
Khokar A., Gupta S. Clinical and Immunological Features of 78 Adult Patients with Primary Selective IgG Subclass Deficiencies // Arch. Immunol. Ther. Exp. (Warsz). 2019. Vol. 67, № 5. P. 325–334.
ESID diagnostic criteria for PID [Electronic resource]. URL: https://esid.org/layout/set/print/content/view/full/12919#Q7.
Seidel M.G. et al. The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity // J. Allergy Clin. Immunol. Pract. 2019. Vol. 7, № 6. P. 1763–1770.
ESID Registry – Working Definitions for Clinical Diagnosis of PID. 2019.
Patel S.Y., Carbone J., Jolles S. The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management // Front. Immunol. 2019. Vol. 10.
Chen X.-F. et al. Clinical characteristics and genetic profiles of 174 patients with X-linked agammaglobulinemia // Medicine (Baltimore). 2016. Vol. 95, № 32. P. e4544.
Sanges S. et al. Diagnosis of primary antibody and complement deficiencies in young adults after a first invasive bacterial infection // Clin. Microbiol. Infect. 2017. Vol. 23, № 8. P. 576.e1-576.e5.
Jolles S. The Variable in Common Variable Immunodeficiency: A Disease of Complex Phenotypes // J. Allergy Clin. Immunol. Pract. 2013. Vol. 1, № 6. P. 545–556.
Gupta S., Pattanaik D., Krishnaswamy G. Common Variable Immune Deficiency and Associated Complications // Chest. 2019. Vol. 156, № 3. P. 579–593.
McCullagh B.N. et al. Antibody deficiency in patients with frequent exacerbations of Chronic Obstructive Pulmonary Disease (COPD) // PLoS One / ed. Kostikas K. 2017. Vol. 12, № 2. P. e0172437.
Orange J.S. et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: A working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology // J. Allergy Clin. Immunol. 2012. Vol. 130, № 3. P. S1–S24.
Özdemir Ö. Current Approach to Primary Immunodeficiency Diseases // South. Clin. Istanbul Eurasia. 2019.
Saha B.K. et al. Molecular and structural characterization of five novel mutations in the Bruton’s tyrosine kinase gene from patients with X-linked agammaglobulinemia. // Mol. Med. 1997. Vol. 3, № 7. P. 477–485.
Yel L. et al. Mutations in the Mu Heavy-Chain Gene in Patients with Agammaglobulinemia // N. Engl. J. Med. 1996. Vol. 335, № 20. P. 1486–1493.
Ferrari S. et al. Mutations of the Igβ gene cause agammaglobulinemia in man // J. Exp. Med. 2007. Vol. 204, № 9. P. 2047–2051.
Minegishi Y. et al. Mutations in Igα (CD79a) result in a complete block in B-cell development // J. Clin. Invest. 1999. Vol. 104, № 8. P. 1115–1121.
Minegishi Y. An Essential Role for BLNK in Human B Cell Development // Science (80-. ). 1999. Vol. 286, № 5446. P. 1954–1957.
Minegishi Y. et al. Mutations in the Human λ5/14.1 Gene Result in B Cell Deficiency and Agammaglobulinemia // J. Exp. Med. 1998. Vol. 187, № 1. P. 71–77.
Tang P. et al. Autosomal Recessive Agammaglobulinemia Due to a Homozygous Mutation in PIK3R1 // J. Clin. Immunol. 2018. Vol. 38, № 1. P. 88–95.
Boisson B. et al. A recurrent dominant negative E47 mutation causes agammaglobulinemia and BCRâ€“ B cells // J. Clin. Invest. 2013. Vol. 123, № 11. P. 4781–4785.
Cunningham-Rundles C. How I treat common variable immune deficiency // Blood. 2010. Vol. 116, № 1. P. 7–15.
Feydy A. et al. Chest high resolution CT in adults with primary humoral immunodeficiency // Br. J. Radiol. 1996. Vol. 69, № 828. P. 1108–1116.
Gharagozlou M. et al. Pulmonary complications in primary hypogammaglobulinemia: a survey by high resolution CT scan // Monaldi Arch. Chest Dis. 2016. Vol. 65, № 2.
Malamut G. et al. The Enteropathy Associated With Common Variable Immunodeficiency: The Delineated Frontiers With Celiac Disease // Am. J. Gastroenterol. 2010. Vol. 105, № 10. P. 2262–2275.
Eropean Medicines Agency. Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg) [Electronic resource]. 2018. URL: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical- investigation-human-normal-immunoglobulin-intravenous-administration-ivig-rev- 3_en.pdf.
World Health Organization. World Health Organization Model List of Essential Medicines 21st List [Electronic resource]. 2019. URL: https://www.who.int/medicines/publications/essentialmedicines/en/.
Radosevich M., Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance // Vox Sang. 2010. Vol. 98, № 1. P. 12–28.
Laursen I.A. et al. Development, Manufacturing and Characterization of a Highly Purified, Liquid Immunoglobulin G Preparation from Human Plasma // Transfus. Med. Hemotherapy. 2014. Vol. 41, № 3. P. 205–212.
Киргизов К.И., Скоробогатова Е.В. Внутривенные иммуноглобулины: применение современных физиологичных растворов способно улучшить результаты терапии // Российский журнал детской онкологии и гематологии. 2015. Vol. 2, № 2. P. 77.
Wasserman R.L. Personalized Therapy: Immunoglobulin Replacement for Antibody Deficiency. // Immunol. Allergy Clin. North Am. 2019. Vol. 39, № 1. P. 95–111.
Ochs H.D., Pinciaro P.J. Octagam ® 5%, an Intravenous IgG Product, Is Efficacious and Well Tolerated in Subjects with Primary Immunodeficiency Diseases // J. Clin. Immunol. 2004. Vol. 24, № 3. P. 309–314.
Stein M.R. et al. Safety and Efficacy of Privigen®, a Novel 10% Liquid Immunoglobulin Preparation for Intravenous Use, in Patients with Primary Immunodeficiencies // J. Clin. Immunol. 2009. Vol. 29, № 1. P. 137–144.
Stein M.R. et al. Safety and efficacy of Home-Based Subcutaneous Immunoglobulin G in Elderly Patients with Primary Immunodeficiency Diseases // Postgrad. Med. 2011. Vol. 123, № 5. P. 186–193.
Латышева Т.В., Латышева Е.А., Мартынова И.А. Место иммуноглобулинов для внутривенного введения в современной клинической практике: новый 10% иммуноглобулин. 2016. № 4. P. 82–87.
Хлудова Л.Г. et al. Оценка эффективности и безопасности 10% внутривенного иммуноглобулина привиджен в реальной клинической практике // Российский аллергологический журнал. 2019. № 4. P. 48–56.
Смирнова И.Н. et al. Фармакоэкономический анализ заместительной терапии внутривенным иммуноглобулином у пациентов с первичными дефектами гуморального звена иммунитета // Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2016. Vol. 15, № 1. P. 66–71.
Garcia-Lloret M., McGhee S., Chatila T.A. Immunoglobulin Replacement Therapy in Children // Immunol. Allergy Clin. North Am. 2008. Vol. 28, № 4. P. 833–849.
Кондратенко И.В., Бологов А.А. Внутривенные иммуноглобулины от создания до наших дней. 2018. № 6. P. 124–132.
Латышева Т.В., Латышева Е.А., Мартынова И.А. Оценка эффективности и безопасности препарата иммуноглобулина для внутривенного введения И.Г.Вена у пациентов с первичным иммунодефицитом с преимущественным нарушением синтеза антитела // Российский аллергологический журнал. 2016. № 1. P. 16–22.
Eijkhout H.W. et al. The Effect of Two Different Dosages of Intravenous Immunoglobulin on the Incidence of Recurrent Infections in Patients with Primary Hypogammaglobulinemia // Ann. Intern. Med. 2001. Vol. 135, № 3. P. 165.
Goudouris E.S. et al. II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies // Einstein (São Paulo). 2017. Vol. 15, № 1. P. 1–16.
Абрамова И.Н., Родина Ю.А., Щербина А.Ю. Эволюция препартов внутривенных иммуноглобулинов и их клинического применения в педиатрической практике // Педиатрия Журнал им Г.Н. Сперанского. 2019. № 4. P. 210–217.
Walsh J.E. et al. Immunoglobulin replacement therapy reduces chronic rhinosinusitis in patients with antibody deficiency // Int. Forum Allergy Rhinol. 2017. Vol. 7, № 1. P. 30– 36.
Joud Hajjar et al. Prophylactic Antibiotics Versus Immunoglobulin Replacement in Specific Antibody Deficiency // J. Clin. Immunol. 2019.
Schwartz H.J. et al. The response to intravenous immunoglobulin replacement therapy in patients with asthma with specific antibody deficiency. // Allergy asthma Proc. Vol. 27, № 1. P. 53–58.
Duse M. et al. Transient Hypogammaglobulinemia of Infancy: Intravenous Immunoglobulin as First Line Therapy // Int. J. Immunopathol. Pharmacol. 2010. Vol. 23, № 1. P. 349–353.
Breslin M.E. et al. Transient hypogammaglobulinemia and severe atopic dermatitis: Open- label treatment with immunoglobulin in a case series // Allergy Rhinol. 2016. Vol. 7, № 2. P. 69–73.
Abdou N.I. et al. Efficacy of Intravenous Gammaglobulin for Immunoglobulin G Subclass and/or Antibody Deficiency in Adults // Int. Arch. Allergy Immunol. 2009. Vol. 149, № 3. P. 267–274.
Abrahamian F., Agrawal S., Gupta S. Immunological and clinical profile of adult patients with selective immunoglobulin subclass deficiency: response to intravenous immunoglobulin therapy // Clin. Exp. Immunol. 2010. Vol. 159, № 3. P. 344–350.
Olinder-Nielsen A.-M. et al. Immunoglobulin prophylaxis in 350 adults with IgG subclass deficiency and recurrent respiratory tract infections: A long-term follow-up // Scand. J. Infect. Dis. 2007. Vol. 39, № 1. P. 44–50.
Hanson L.A. et al. IgG subclass deficiency with or without IgA deficiency. // Clin. Immunol. Immunopathol. 1991. Vol. 61, № 2 Pt 2. P. S70-7.
Quartier P. et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: A retrospective survey of 31 patients // J. Pediatr. 1999. Vol. 134, № 5. P. 589–596.
Gelfand E.W. Differences between IGIV products: Impact on clinical outcome // Int. Immunopharmacol. 2006. Vol. 6, № 4. P. 592–599.
Sun A., Teschner W., Yel L. Improving patient tolerability in immunoglobulin treatment: focus on stabilizer effects // Expert Rev. Clin. Immunol. 2013. Vol. 9, № 6. P. 577–587.
Chérin P., Cabane J. Relevant Criteria for Selecting an Intravenous Immunoglobulin Preparation for Clinical Use // BioDrugs. 2010. Vol. 24, № 4. P. 211–223.
Щербина А.. Маски первичных иммунодефицитных состояний: проблемы диагностики и терапии // Российский журнал детской онкологии и гематологии. 2016. № 1. P. 52–58.
Camcoglu Y. Immunoglobulin Treatment of Immunodeficient Patients // Immunodeficiency. InTech, 2012.
Maarschalk-Ellerbroek L.J., Hoepelman I.M., Ellerbroek P.M. Immunoglobulin treatment in primary antibody deficiency // Int. J. Antimicrob. Agents. 2011. Vol. 37, № 5. P. 396– 404.
Brown K.E., Young N.S. Parvoviruses and Bone Marrow Failure // Stem Cells. 1996. Vol. 14, № 2. P. 151–163.
Adams S.T.M. et al. Common Variable Immunodeficiency Presenting With Persistent Parvovirus B19 Infection // Pediatrics. 2012. Vol. 130, № 6. P. e1711–e1715.
Ruiz Gutiérrez L. et al. Parvovirus B19 chronic monoarthritis in a patient with common variable immunodeficiency // Reumatol. Clínica. 2015. Vol. 11, № 1. P. 58–59.
Shapiro R.S. Why I Use Subcutaneous Immunoglobulin (SCIG) // J. Clin. Immunol. 2013. Vol. 33, № S2. P. 95–98.
Shabaninejad H. et al. A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis // Expert Rev. Clin. Immunol. 2016. Vol. 12, № 5. P. 595–602.
Bonilla F.A. Intravenous and subcutaneous immunoglobulin G replacement therapy // Allergy Asthma Proc. 2016. Vol. 37, № 6. P. 426–431.
N. Shah S., Todoric K., . Tarrant T.K. Improved outcomes on subcutaneous IgG in patients with humoral immunodeficiency and co-morbid bowel disease // Clin. Case Reports Rev. 2015. Vol. 1, № 7.
Garbett N.D., Currie D.C., Cole P.J. Comparison of the clinical efficacy and safety of an intramuscular and an intravenous immunoglobulin preparation for replacement therapy in idiopathic adult onset panhypogammaglobulinaemia. // Clin. Exp. Immunol. 1989. Vol. 76, № 1. P. 1–7.
García Rodríguez C. et al. [Treatment of primary immunodeficiencies with intravenous gamma globulin]. // An. Esp. Pediatr. 1987. Vol. 27, № 6. P. 411–415.
Kuruvilla M., de la Morena M.T. Antibiotic Prophylaxis in Primary Immune Deficiency Disorders // J. Allergy Clin. Immunol. Pract. 2013. Vol. 1, № 6. P. 573–582.
Латышева Т.В. et al. Успешное лечение гранулематозной лимфоцитарной интерстициальной болезни легких у пациента с ОВИН (описание клинического случая) // Российский аллергологический журнал. 2016. № 4–5. P. 72–76.
Bethune C. et al. British Society for Immunology/United Kingdom Primary Immunodeficiency Network consensus statement on managing non‐infectious complications of common variable immunodeficiency disorders // Clin. Exp. Immunol. 2019. Vol. 196, № 3. P. 328–335.
Schwimmer D., Glover S. Primary Immunodeficiency and the Gut // Gastroenterol. Clin. North Am. 2019. Vol. 48, № 2. P. 199–220.
Kamae C. et al. Common variable immunodeficiency classification by quantifying T-cell receptor and immunoglobulin κ-deleting recombination excision circles // J. Allergy Clin. Immunol. 2013. Vol. 131, № 5. P. 1437-1440.e5.
Nakagawa N. et al. Quantification of κ-deleting recombination excision circles in Guthrie cards for the identification of early B-cell maturation defects // J. Allergy Clin. Immunol. 2011. Vol. 128, № 1. P. 223-225.e2.
Korsunskiy I. et al. TREC and KREC Levels as a Predictors of Lymphocyte Subpopulations Measured by Flow Cytometry // Front. Physiol. 2019. Vol. 9. P. 1877.
Rubin L.G. et al. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host // Clin. Infect. Dis. 2014. Vol. 58, № 3. P. e44–e100.
Sobh A., Bonilla F.A. Vaccination in Primary Immunodeficiency Disorders // J. Allergy Clin. Immunol. Pract. 2016. Vol. 4, № 6. P. 1066–1075.
Martire B. et al. Vaccination in immunocompromised host: Recommendations of Italian Primary Immunodeficiency Network Centers (IPINET) // Vaccine. 2018. Vol. 36, № 24. P. 3541–3554.
Eibl M.M., Wolf H.M. Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities // Immunotherapy. 2015. Vol. 7, № 12. P. 1273–1292.
Латышева Т.В. et al. Вакцинация больных с первичными иммунодефицитами: современный взгляд на проблему // Российский аллергологический журнал. 2017. № 3. P. 19–26.
Хаитов Р.. М., Сухих Г.Т. Ведение больных с Первичным иммунодефицитом в акушерстве. 2012.
Brinker K.A., Silk H.J. Common variable immune deficiency and treatment with intravenous immunoglobulin during pregnancy // Ann. Allergy, Asthma Immunol. 2012. Vol. 108, № 6. P. 464–465.
Cunningham-Rundles C. Key aspects for successful immunoglobulin therapy of primary immunodeficiencies // Clin. Exp. Immunol. 2011. Vol. 164. P. 16–19.
Gardulf A. et al. Rapid subcutaneous IgG replacement therapy at home for pregnant immunodeficient women. // J. Clin. Immunol. 2001. Vol. 21, № 2. P. 150–154.
Palmeira P. et al. Transfer of antibodies across the placenta and in breast milk from mothers on intravenous immunoglobulin // Pediatr. Allergy Immunol. 2009. Vol. 20, № 6. P. 528–535.

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница

Приложение А3. Справочные материалы, включая соответствие показаний к применению и противопоказаний, способов применения и доз лекарственных препаратов инструкции по применению лекарственного препарата

Приложение А3.1 связанные документы

Приложение А3.2. Международная классификация ПИД (IUIS), основанная на выявляемом генетическом дефекте. [11]

Приложение А3.4 Требования, предъявляемые Всемирной организацией здравоохранения и Европейской фармакопеей, FDA к современным препаратам иммуноглобулина человек нормального.

Приложение Б. Алгоритмы действий врача

Приложение Б.1 Алгоритм диагностики ПИД с дефектом гуморального звена иммунитета

Приложение В. Информация для пациента

Данный блок поддерживает скрол*